Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I First-In-Human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CRPA1A2, a Bispecific T Cell Engager, in Patients With HLA-A*02:01 and MAGE-A1 Positive Advanced Solid Tumors

NCT07583316 is registered in ClinicalTrials.gov with Corregene Biotechnology Co., Ltd as lead sponsor.

NCT NCT07583316
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07583316 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I First-In-Human Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CRPA1A2, a Bispecific T Cell Engager, in Patients With HLA-A*02:01 and MAGE-A1 Positive Advanced Solid Tumors
Lead sponsor
Corregene Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 29, 2026
Completion date
September 30, 2030
Enrollment
192 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophagus cancer, head and neck cancer, hepatocellular carcinoma (hcc), lung cancer (locally advanced or metastatic)